Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- PMID: 22388760
- DOI: 10.1038/modpathol.2012.36
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Abstract
Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene amplification has been reported to occur with variable frequencies in breast cancers. However, there have been few studies of its clinicopathological significance. We used tissue microarrays to evaluate two aspects of intratumoral heterogeneity of HER2 gene amplification: regional heterogeneity and genetic heterogeneity. We examined 96 invasive breast cancers in which HER2 amplification had been diagnosed in whole sections, and determined the clincopathological characteristics of those tumors. HER2 regional heterogeneity, defined as the existence of amplification/negative or amplification/equivocal patterns in different tissue microarray cores of a tumor, was present in 17 (18%) of the 96 cases. HER2 genetic heterogeneity, defined as the presence of tumor cells with a HER2/chromosome enumeration probe 17 ratio higher than 2.2 in 5-50% of the tumor cells, was found in 11 cases (11%), all of which showed HER2 regional heterogeneity. The cases with intratumoral heterogeneity of HER2 gene amplification were characterized by low grade or equivocal HER2 amplification and equivocal (2+) HER2 expression in whole sections. The patients with intratumoral heterogeneity of HER2 gene amplification had significantly shorter disease-free survival times than those with homogeneous HER2 gene amplification, and this effect was also evident in subgroup analysis by hormone receptor status. In multivariate analysis, intratumoral HER2 heterogeneity retained its status as an independent prognostic factor for disease-free survival. In conclusion, intratumoral heterogeneity of HER2 gene amplification is present in a subset of HER2-amplified breast cancers, especially in cases with low-grade HER2 amplification and equivocal HER2 expression, indicating a need for HER2 testing on more representative, larger tumor samples for accurate assessment of HER2 status in such cases. The patients with this heterogeneity have decreased disease-free survival, suggesting that genetic instability, and hence aberrant HER2 amplification in subclones of such tumors, may be associated with breast cancer progression.
Comment in
-
HER-2 intratumoral heterogeneity.Mod Pathol. 2013 Apr;26(4):607-9. doi: 10.1038/modpathol.2012.147. Mod Pathol. 2013. PMID: 23542522 No abstract available.
-
Letter to the editor regarding 'Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.Mod Pathol. 2013 Apr;26(4):609-10. doi: 10.1038/modpathol.2012.213. Mod Pathol. 2013. PMID: 23542523 No abstract available.
-
Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.Mod Pathol. 2013 Apr;26(4):610-1. doi: 10.1038/modpathol.2013.38. Mod Pathol. 2013. PMID: 23542524 No abstract available.
-
In Reply.Arch Pathol Lab Med. 2016 Aug;140(8):741. doi: 10.5858/arpa.2016-0105-LE. Arch Pathol Lab Med. 2016. PMID: 27472229 No abstract available.
Similar articles
-
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.Am J Clin Pathol. 2015 Oct;144(4):570-8. doi: 10.1309/AJCP51HCGPOPWSCY. Am J Clin Pathol. 2015. PMID: 26386078
-
HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.Am J Clin Pathol. 2014 Dec;142(6):755-66. doi: 10.1309/AJCPIRL4GUVGK3YX. Am J Clin Pathol. 2014. PMID: 25389328
-
Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.Am J Clin Pathol. 2009 May;131(5):678-82. doi: 10.1309/AJCP09VUTZWZXBMJ. Am J Clin Pathol. 2009. PMID: 19369627
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
-
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.Braz J Med Biol Res. 2013 Mar;46(3):207-16. doi: 10.1590/1414-431x20132483. Epub 2013 Mar 19. Braz J Med Biol Res. 2013. PMID: 23558859 Free PMC article. Review.
Cited by
-
Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists.J Pers Med. 2024 Apr 28;14(5):467. doi: 10.3390/jpm14050467. J Pers Med. 2024. PMID: 38793049 Free PMC article. Review.
-
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.iScience. 2024 Apr 15;27(5):109750. doi: 10.1016/j.isci.2024.109750. eCollection 2024 May 17. iScience. 2024. PMID: 38711454 Free PMC article.
-
Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status.Breast Cancer. 2024 Jul;31(4):705-716. doi: 10.1007/s12282-024-01585-3. Epub 2024 Apr 21. Breast Cancer. 2024. PMID: 38643429 Free PMC article.
-
Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.Med Mol Morphol. 2024 Apr 15. doi: 10.1007/s00795-024-00386-z. Online ahead of print. Med Mol Morphol. 2024. PMID: 38619618
-
High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer.Cancers (Basel). 2024 Mar 5;16(5):1062. doi: 10.3390/cancers16051062. Cancers (Basel). 2024. PMID: 38473420 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous